Cholera Vaccines Market Introduction and Overview
According to SPER Market Research, the Global Cholera Vaccines Market is estimated to reach USD 222.23 million by 2034 with a CAGR of 8.63%.
The report includes an in-depth analysis of the Global Cholera Vaccines Market, including market size and trends, product mix, Applications, and supplier analysis. The Cholera Vaccines Market was valued at USD 97.12 million in 2024 and is expected to expand at an 8.63% CAGR from 2025 to 2034, owing to the increasing global burden of cholera outbreaks, particularly in places with inadequate water and sanitation facilities. Furthermore, increased awareness and initiatives by governments and international organizations to execute mass vaccination campaigns have boosted market demand. Furthermore, increased travel to endemic areas drives up demand for cholera vaccines, as does the development of more accessible and cheap travel vaccine formulations, which improves immunization efforts and market penetration.
By Type Insights: The killed oral o1 and o139 segment led the market and had the highest revenue share in 2024. Its growth is due to effective vaccination strategies and heightened awareness. Prevention measures, like oral administration and vaccination campaigns, are improving. Increased cholera cases have pushed public health agencies to focus on vaccines as a key defense against climate change and urbanization.
By Product Insights: Dukoral led the market and held the largest revenue share in 2024 due to improved awareness and successful prevention methods. It offers protection against vibrio cholerae O1 and enterotoxigenic Escherichia coli. Its oral form avoids injections, making it easier for patients. As cholera continues to be a problem in areas like Africa and Asia Pacific, the vaccine is crucial for public health and vaccination efforts. Its oral method simplifies distribution and administration.
By Distribution Channel Insights: Hospital pharmacies in the distribution channel segment led the market in 2024, holding the largest revenue share due to their proper storage, administration of vaccines, and integrated patient care systems. They have the infrastructure needed to maintain the cold chain for vaccines, vital for sensitive products like cholera vaccines.
Regional Insights: North America cholera vaccines market dominated the global market and accounted for the largest revenue share in 2024, due to increased awareness and preventive measures. Although cholera is not common in North America, the region significantly funds global health initiatives, including providing vaccines to high cholera incidence countries. Rising concerns about international travel and migration have also emphasized the need for vaccination to protect travelers and humanitarian workers in cholera-prone areas.
Market Competitive Landscape:
The cholera vaccine industry is highly competitive, with multiple pharmaceutical and biotech companies fighting for dominance. These companies are at the forefront of developing cutting-edge vaccine formulations, increasing production capacity, and expanding global distribution networks. They work strategically with research institutes and international organizations to boost research and development efforts and accelerate regulatory clearances. Furthermore, considerable investments in innovative vaccination technology demonstrate their commitment to satisfying the growing demand for effective cholera prevention measures in high-risk locations worldwide.
Recent Developments:
In February 2023, Emergent BioSolutions Inc. partnered with Bavarian Nordic. The company acquired rights to the Vaxchora vaccine and Emergent’s manufacturing site in Bern, Switzerland, along with facilities in San Diego, California. About 280 Emergent employees are expected to join the company.
In August 2023, GC Biopharma and Eubiologics signed a memorandum of understanding (MOU) for the co-production of Euvichol, an oral cholera vaccine. Eubiologics will handle bulk production, while GC Biopharma will manage packaging, including vial bottling. This partnership aims to improve production and distribution of Euvichol to meet global health needs.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Type, By Product, By Distribution Channel. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Valneva SE, Sanofi S.A, Astellas Pharma, Inc, Emergent BioSolutions Inc, PavVax Inc, EuBiologics Co., Ltd, Shantha Biotechnics Limited, Hilleman Laboratories, Astellas Pharma Inc, Incepta Vaccine Ltd, Vabiotech. and others. |
Key Topics Covered in the Report:
- Global Cholera Vaccines Market Size (FY’2021-FY’2034)
- Overview of Global Cholera Vaccines Market
- Segmentation of Global Cholera Vaccines Market By Type (Whole Cell v. Cholerae O1 with Recombinant B- subunit, Killed Oral O1 and O139)
- Segmentation of Global Cholera Vaccines Market By Product (Vaxchora, Dukoral, Shanchol, Other products)
- Segmentation of Global Cholera Vaccines Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other)
- Statistical Snap of Global Cholera Vaccines Market
- Expansion Analysis of Global Cholera Vaccines Market
- Problems and Obstacles in Global Cholera Vaccines Market
- Competitive Landscape in the Global Cholera Vaccines Market
- Details on Current Investment in Global Cholera Vaccines Market
- Competitive Analysis of Global Cholera Vaccines Market
- Prominent Players in the Global Cholera Vaccines Market
- SWOT Analysis of Global Cholera Vaccines Market
- Global Cholera Vaccines Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Cholera Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cholera Vaccines Market
7. Global Cholera Vaccines Market, By Type (USD Million) 2021-2034
7.1. Whole Cell v. Cholerae O1 with Recombinant B- subunit
7.2. Killed Oral O1 and O139
8. Global Cholera Vaccines Market, By Product (USD Million) 2021-2034
8.1. Vaxchora
8.2. Dukoral
8.3. Shanchol
8.4. Other products
9. Global Cholera Vaccines Market, By Distribution Channel (USD Million) 2021-2034
9.1. Hospital Pharmacy
9.2. Retail Pharmacy
9.3. Other
10. Global Cholera Vaccines Market, (USD Million) 2021-2034
10.1. Global Cholera Vaccines Market Size and Market Share
11. Global Cholera Vaccines Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. Valneva SE
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Sanofi S.A
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Emergent BioSolutions Inc
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. PaxVax Inc
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. EuBiologics Co., Ltd
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Shantha Biotechnics Limited
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Hilleman Laboratories
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Astellas Pharma Inc
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Incepta Vaccine Ltd
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Vabiotech
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
